Rectal Cancer: Will I Need a Permanent Colostomy Bag?

What do the different stoma options mean?

The rectum is the last part of the large bowel, just above the anus. A stoma is an opening made through the abdominal wall so bowel contents can leave into a bag. A colostomy uses the colon, or large bowel; an ileostomy uses the end of the small bowel. They are different operations, although people sometimes call both a “colostomy bag”.

This article concerns rectal cancer. Colon cancer and anal cancer have different treatment pathways. For more about diagnosis and treatment, read our full guide to rectal cancer.

These are possible treatment plans, not a way to classify yourself from a report. Ask your surgeon to name the proposed operation and draw what will be removed, joined or diverted.

What determines whether I need a permanent colostomy?

For locally advanced rectal cancer, a dedicated pelvic magnetic resonance imaging (MRI) helps show the tumour's relationship to nearby tissues, lymph nodes, the anal sphincters and the planned surgical margin. Sphincters are the muscles that help control when stool passes. The team combines MRI findings with examination, endoscopy (looking inside the bowel with a camera), biopsy and tests to establish the cancer’s stage.

The central surgical question is whether the tumour can be removed safely while preserving useful bowel control. A key aim is an adequate cancer-free margin around the tumour. The pathologist checks both whether cancer reaches a cut edge and how close it comes to the outer margin around the rectum.

A low anterior resection removes the affected rectum and reconnects the bowel. An abdominoperineal resection removes the rectum and anus and requires a permanent stoma. Which operation is appropriate depends on more than tumour height.

Your current bowel control, general health, healing risks and likely function after reconnection also matter. A technically possible connection may still leave difficult symptoms. Ask the colorectal surgeon to explain these trade-offs using your own MRI and examination findings.

Decisions belong in a multidisciplinary team discussion, involving colorectal surgery, oncology, radiology and pathology, with stoma-nursing input. The recommendation may change after treatment and reassessment.

Why might treatment come before surgery?

Treatment given before an operation is called neoadjuvant treatment. For appropriate locally advanced cancers, total neoadjuvant therapy, or TNT, gives chemotherapy and radiotherapy or chemoradiotherapy before planned surgery. Chemoradiotherapy combines radiation with chemotherapy.

The sequence aims to improve cancer control and may create an opportunity to preserve the rectum. It is not needed for every rectal cancer. The initial stage, MRI risk features, tumour biology, health and goals determine which approach fits. A tumour becoming smaller does not guarantee a bowel connection, stoma avoidance or omission of surgery.

Before starting, ask: “What is this treatment trying to achieve, when will my response be assessed, and who will reconsider the operation?” Having those steps written down can make an uncertain period easier to navigate.

Can some people avoid rectal surgery?

Some carefully selected patients can discuss watch-and-wait, also called non-operative management, after a clinical complete response (cCR) to treatment. This means the planned assessments find no remaining tumour that can be detected. It is not proof that every cancer cell has gone or that the cancer is cured.

Assessment involves more than a clear scan: it brings together rectal examination, endoscopy and pelvic MRI, with wider assessment for disease elsewhere. An incomplete response is not a complete response. A near-complete response needs expert reassessment rather than an assumption that surgery is unnecessary.

Watch-and-wait is an active programme of scheduled examinations, endoscopy and imaging. Research provides longer-term evidence for organ preservation in selected patients with stage 2 or 3 rectal cancer treated with TNT. It also documents local tumour regrowth — cancer becoming detectable again in or near the rectum — most often within the first two years.

Regrowth may require surgery, potentially including a permanent stoma. Surgery remains possible for many patients when regrowth is detected, but successful treatment of regrowth cannot be promised. Ask about the team's experience, the written surveillance schedule, the ability to attend every visit and what happens if an assessment is suspicious.

Could immunotherapy change my options?

It can for a particular biological group. Mismatch repair, or MMR, is a cell system that corrects errors when cells copy their DNA, the genetic material that carries instructions for how cells work. When this repair system does not work properly, it is called deficient mismatch repair (dMMR). High microsatellite instability (MSI-H) is a related finding on tumour DNA testing. These test findings, called biomarkers, can help identify rectal cancers that may respond to immunotherapy. Ask whether your biopsy has had MMR/MSI testing. These results should inform treatment planning.

The guideline: the American Society of Clinical Oncology (ASCO) rectal cancer guideline recommends immunotherapy for MSI-H/dMMR locally advanced rectal cancer. This is a recommendation for a defined group, with individual assessment of suitability.

The newer evidence: The global AZUR-1 trial studied dostarlimab alone in adults with previously untreated stage 2 or 3 dMMR/MSI-H locally advanced rectal cancer. Its first peer-reviewed report appeared online on 25 October 2026. This interim report supports the possibility of avoiding chemotherapy, radiotherapy and surgery in some patients, while others needed additional treatment. The trial had no comparison group, and longer follow-up is needed; it does not establish a cure rate.

The US approval: On 19 October 2026, the US Food and Drug Administration (FDA) granted accelerated approval to dostarlimab as a single agent for adults with stage 2 or 3 locally advanced rectal cancer that is MSI-H or dMMR, determined by an FDA-authorised test for solid tumours. Approval was based on clinical complete response lasting at least 12 months. The prescribing information states that long-term relapse risk is unknown; continued approval may depend on confirmatory evidence of clinical benefit.

Immunotherapy may cause side effects, including inflammation when the immune system affects healthy organs such as the bowel, lungs, liver or hormone glands. Your team monitors you through appointments and blood tests and will explain which symptoms to report promptly. Some reactions can be serious and need early treatment. Regular assessment of the cancer and ongoing follow-up remain important; immunotherapy is suitable for particular groups of patients and does not replace standard treatment for every rectal cancer.

What if a permanent stoma is the safest choice?

Needing a permanent stoma is not a personal failure. It can be part of an effective cancer operation and a practical route to recovery. You should have time to discuss what living with it would mean for you.

A stoma nurse can help with bag fitting, skin care, supplies and learning how to manage changes. Ask to meet the nurse before a planned operation, including discussion of the best position for the stoma. Before discharge, make sure you know whom to contact if the bag leaks, skin becomes sore or you feel unable to cope.

Many people return to work and valued activities after recovery. Relationships and intimacy can continue, although adjustment takes time. Practical teaching, rehabilitation and emotional support matter alongside the operation.

Preserving the anus does not guarantee normal bowel function. Low anterior resection syndrome, or LARS, can include urgency, frequent bowel movements, several trips close together and leakage. Symptoms may improve but can persist; tell the team so they can discuss management. Compare the likely daily experience of each option, including a stoma, rather than judging success only by whether a bag is avoided.

What should I ask before treatment is finalised?

Use these questions to make the recommendation specific:

• What does my pelvic MRI show about the sphincters and the margin around the tumour?
• What operation are you recommending, and why? Could treatment response change it?
• Is the proposed stoma intended to be temporary or permanent? What could prevent reversal?
• What bowel control and daily function are realistic with each reasonable option?
• What are my MMR/MSI results? Is organ preservation appropriate, and what are its uncertainties?
• If I choose watch-and-wait, what appointments are required, who organises them and what triggers surgery?
• What is the next step, and when should it happen?

Bring the biopsy and MMR/MSI reports, colonoscopy findings, pelvic MRI report and images, staging scans and previous treatment records. Include current medicines, important illnesses and a brief account of bowel control before treatment. If something is missing, ask the team how to obtain it.

Discuss your rectal cancer treatment options with the oncology and colorectal surgical teams. A review can clarify why a stoma is advised, which alternatives deserve consideration and what further assessment is needed. The aim is a plan that accounts for cancer control, likely bowel function and your priorities.

When should I seek urgent help?

Severe or worsening abdominal pain, a swollen abdomen, vomiting and inability to pass stool or wind can indicate bowel obstruction. Seek urgent hospital assessment. Heavy bleeding, fainting or rapid deterioration also need urgent care. Do not delay treatment for an urgent complication while seeking a stoma-avoidance opinion.

Bringing the discussion together

You do not need to resolve every question on your own. Bring your available reports and the questions that matter most to your treating team. Before leaving, check that you understand the agreed next step, when it should happen and whom to contact if you need help.